<DOC>
	<DOCNO>NCT01092780</DOCNO>
	<brief_summary>This study safety efficacy MK-7288 treatment excessive daytime sleepiness ( EDS ) participant obstructive sleep apnea ( OSA ) /hypopnea syndrome ( HS ) compliant effective nasal continuous positive airway pressure ( nCPAP ) therapy . The goal study determine effect MK-7288 single dose administration promote wakefulness measure sleep latency Maintenance Wakefulness Tests , drive performance measure standard deviation lane position simulate driving ( country vigilance drive ) .</brief_summary>
	<brief_title>Pharmacodynamics Efficacy MK-7288 Adults With Sleep Apnea ( MK-7288-010 )</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Female participant nonchildbearing potential . Male participant female partner ( ) childbearing potential must agree use medically acceptable method contraception study . Participant International Classification Sleep Disorders diagnosis Obstructive Sleep Apnea/Hypopnea Syndrome . Participant excessive daytime sleepiness . Participant use nCPAP treatment least 2 month . Participant report total sleep time &gt; 6 hour least 4 7 night week Participant willing stay sleep laboratory 5 overnight stay . Participant willing limit caffeine alcohol consumption study . Participant valid driver 's license past 5 year least 1 year drive experience within past 3 year . Participant 's regular bedtime 9:00 p.m. 12:00 a.m . Participant history cancer . Participant history significant neurological disorder . Participant moderate severe persistent asthma . Participant history follow sleep disorder : narcolepsy , primary insomnia , Circadian rhythm sleep disorder , shift work sleep disorder , parasomnia include nightmare disorder , sleep terror disorder , rapid eye movement ( REM ) behavioral disorder , sleepwalk disorder , periodic limb movement disorder , restless leg syndrome . Participant consume 10 cigarette day routinely smokes night . Participant , opinion investigator , history current evidence condition , therapy , lab abnormality circumstance might confound result study , interfere participation full duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>